Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Auride Completes First Phase of Computing Power RWA Issuance with Asset Scale Reaching Tens of Millions of RMB

Auride Completes First Phase of Computing Power RWA Issuance with Asset Scale Reaching Tens of Millions of RMB

金色财经金色财经2025/08/08 11:17
Show original

According to Jinse Finance, on August 8, Aorui De, with the support of Ant Digital Technologies, successfully completed the first phase issuance of RWA (Real World Assets) based on AI server assets, with an asset scale of tens of millions of RMB. The underlying assets of this project are AI servers owned by Aorui De’s subsidiary, Shenzhen Zhisuannli Digital Technology Co., Ltd., marking the nation’s first RWA backed by computing power assets. During this RWA issuance, both parties strictly screened the compliance, income quality, and status of the on-chain assets to ensure the authenticity of the assets and the traceability of the data. On one hand, Aorui De leveraged AntChain technology to record AI server operation information on-chain, ensuring the security, transparency, and immutability of asset data, as well as the transparency and verifiability of returns. On the other hand, this RWA was issued overseas through compliant channels, effectively attracting foreign capital and opening up a new path for cross-border financing.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage